ANEMIYa, OBUSLOVLENNAYa ONKOLOGIChESKIMI ZABOLEVANIYaMI: SOVREMENNOE SOSTOYaNIE PROBLEMY I ROL' VNUTRIVENNYKh PREPARATOV ZhELEZA
- Authors: Volkova S.A1
-
Affiliations:
- Issue: No 8 (2013)
- Pages: 56-58
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/281173
- ID: 281173
Cite item
Open Access
Access granted
Abstract
Cancer-associated anemia (CAA) is the most important multifactorial problem. The efficacy and safety of different treatments of CAA, primarily monotherapy with erythropoiesis-stimulating agents, their combination with oral or injectable iron supplements have been studied in numerous randomized clinical trials and meta-analyzes. The article presents the main aspects of the problem with the review of the most recent significant publications and recommendations. The use of ferric carboxymaltosate improves efficacy of antianemic therapy in cancer patients. Possibility of effective use of ferric carboxymaltosate as monotherapy in absolute or functional iron deficiency actualizes the significance of mandatory monitoring of serum ferritin levels and transferrin saturation in cancer patients
Full Text
References
- Ludwig H., Van B.S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306.
- Caro J.J., Salas M., Ward A., et al. Anemia as an independent prognostic factor for survival in patients with cancer; a systemic, quantitative review. Cancer 2001;91;2214-21.
- Henry D. Parenteral Iron Therapy in Cancer-Associated Anemia. Hematology Am Soc Hematol Educ Program 2010;2010:351-56.
- Verdon F., Burnand B., Stubi C.L., et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomized placebo controlled trial. BMJ 2003;326(7399):1124.
- Rizzo J.D., Brouwers M., Hurley P., et al. American Society of Hematology/American Society of Clinical Oncology practice guideline update on the use of epoetin and darbopoetin in adult patients with the cancer. Blood 2010:116:4045-59.
- Henry D. Iron or vitamine B12 deficiency in anemic cancer patient prior to erythropoieses-stimulating agent therapy. Community Oncology 2007;4:95-101.
- Petrelly F., Borgonovo K., Cabiddu M., et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. Cancer Res Clin Oncol 2012;138(2):179-87.
- Steinmetz H.T., Tsamaloukas A., Schmitz S., et al. A new concept for differential diagnosis and therapy of anemia in cancer patients. Support Care Cancer 2010;19:261-69.
- Crishton R.R., Danielson B.G., Geisser P. Iron therapy with special emphasis on intravenous administration. 4th edition. London, Bioston: International Medical Publishers; 2008.
- Ferric carboxymaltosat: a breakthrough treatment for iron deficiency anaemia. EJHP Practice 2009;15(5);62-5.
- Lyseng-Williamson K.A., Keating G.M. Ferric carboxymaltose: a review of its use in iron-deficiency anemia. Drug 2009;69(6):739-56.
- Moore R.A., Gaskell H., Rose P., Allan G. Metaanalysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial date. BMC Blood Disord 2011;11:4.
- Steimnetz H., Tschechne B., Harlin O., et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anemia. Ann Oncol 2013;24:475-82.
- Beale A.L., Penney M.D., Alison M.C. The prevalence of iron deficiency among patients presentation with colorectal cancer. Colorectal Dis 2005;7:398-402.
- Aapro M., Osterborg A., Gascon P., et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012;23:1954-62.
- Ludwig H., Müldür E., Endler G., et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 2011; 96:abstr. 982.
- Ludwig H., Aapro M., Bokemeyer C., et al. Treatment patterns and outcomes in management of anemia in cancer patients in Europe; finding from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 2009;45;1603-15.
- Glaspy J., Crawford J., Vansteenkiste J., et al. Erythropoiesis-stimulating agents in oncology; a study-evel meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102:301-15.
- National Comprehensive Cancer Network Inc. NCCN Practice Guideline in Oncology; Cancer and Chemitherapy-Induced Anemia - v2.2012 http//nccn.org/professional/physician_gls/ PDF/anemia.pdf
Supplementary files
